Next-Generation Bispecific Nanobody Immunotherapy Targeting CD3 Complex and VTCN1 for Solid Tumors
VHH-P834 is a humanized nanobody-based bispecific antibody fusion construct currently in the Biological Testing stage, designed for the treatment of solid tumors. This innovative candidate targets two key molecules: CD3 Complex (T Cell Receptor Complex) and V-set domain containing T cell activation inhibitor 1 (VTCN1). By engaging both immune cell activation pathways and tumor-associated inhibitory signals, VHH-P834 aims to deliver a dual mechanism immunotherapeutic approach to overcome tumor immune resistance. This unique modality holds significant potential to address unmet needs in solid tumor immunotherapy.
| Candidate | VHH-P834 |
| Target | CD3 Complex (T Cell Receptor Complex) V-set domain containing T cell activation inhibitor 1 (VTCN1) |
| Modality | humanized bispecific VHH |
| Indication | Solid Tumor |
Licensing Opportunity
VHH-P834 is available for out-licensing and collaborative development partnerships. We welcome inquiries from organizations seeking to advance next-generation immunotherapies in the solid tumor field.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P834 |
Modality
VHH-P834 utilizes a bispecific antibody architecture composed of two single-domain antibodies (nanobodies; VHH) directed against VTCN1, fused with an antigen-binding fragment (Fab) specific for CD3, all joined via a human Fc domain. The nanobody components confer small molecular size, high stability, and enhanced tumor tissue penetration, enabling effective engagement within dense tumor microenvironments. This structural design leverages favorable pharmacokinetics and manufacturability while providing robust immune synapse formation between T cells and tumor cells. VHH-P834’s modular format is particularly advantageous for treating solid tumors, where deep and efficient targeting is necessary to drive meaningful therapeutic responses.
Target
CD3 Complex and VTCN1 are pivotal immunological targets in solid tumor therapy. CD3 Complex, a protein assembly found on the surface of T cells, is integral to T cell activation and adaptive immune response orchestration. VTCN1 is an immune checkpoint protein mainly expressed on malignant cells in various solid tumors, where it suppresses anti-tumor immunity. By simultaneously targeting CD3 Complex and VTCN1, VHH-P834 directly engages immune effector cells while blocking tumor-mediated immunosuppression. CD3 Complex activation facilitates T cell recruitment and cytotoxicity, whereas inhibition of VTCN1 disrupts a key tumor defense mechanism. This dual-targeting strategy capitalizes on the strategic value of both CD3 Complex and VTCN1 for combinatorial immunotherapy and offers significant differentiation compared to single-target agents.
Mechanism of Action
VHH-P834 exerts its anti-tumor effects via dual engagement of CD3 Complex on T cells and VTCN1 on tumor cells. The anti-CD3 domain prompts T cell activation and proliferation, enabling immune effector cell recruitment to sites of tumor growth. Concurrently, the anti-VTCN1 component operates as an immune checkpoint inhibitor by blocking a key inhibitory signal exploited by tumors. This coordinated mechanism supports potent T cell-mediated cytotoxicity within the immunosuppressive tumor microenvironment. As a bispecific nanobody construct, VHH-P834’s innovative platform has the potential for expansion into additional modular formats, including antibody-drug conjugates or further multispecific designs, to address evolving therapeutic needs.
Solid Tumor
Solid tumors represent a diverse group of malignancies originating from epithelial, mesenchymal, or connective tissues throughout the body, such as lung, breast, colon, and prostate cancers. Globally, solid tumors constitute the majority of cancer diagnoses and contribute substantially to cancer-related mortality. Current therapeutic approaches include surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapies. However, standard treatments are often limited by systemic toxicity, resistance mechanisms, and suboptimal outcomes, especially in advanced or metastatic settings. Immunotherapies targeting immune checkpoints and T cell engagement have shown promise but are hampered by tumor immune evasion and heterogeneity. Unmet needs include improved response rates, enhanced safety, and durable remission. By harnessing dual immune activation and checkpoint blockade, VHH-P834 has the potential to provide a superior clinical benefit in the treatment of solid tumors.